Five Facts: Pfizer’s and Allergan’s Top Lawyers

On Wednesday, the $160 billion merger between pharmaceutical giants Pfizer and Allergan was called off in response to new U.S. Treasury Department regulations aimed at preventing so-called inversion deals — which allow U.S. companies to move their bases overseas in search of more favorable tax environments.

The combination would have been a record size for pharmaceutical companies , and was also big business for law firms: six different firms were involved in negotiating the deal.

The failure of the deal means Pfizer will keep paying higher U.S. tax rates. It also means the companies’ chief lawyers, Bob Bailey and Doug Lankler (neither of whom were immediately ...